Skip to main content
. 2021 Nov 25;12:777483. doi: 10.3389/fneur.2021.777483

Table 1.

Univariate regression analysis of poor prognosis in patients with gastrointestinal malignant tumor-related AIS.

Item Total (68) Good prognosis (18) Poor prognosis (50) P-value
Male, n (%) 49 (72.06) 14 (77.78) 35 (70.00) 0.528
Age, years 61.78 ± 6.65 61.78 ± 6.11 61.78 ± 6.90 0.741
Hypertension, n (%) 45 (66.18) 9 (50.00) 36 (72.00) 0.091
Diabetes, n (%) 38 (55.88) 7 (38.89) 31 (62.00) 0.090
Hyperlipidemia, n (%) 43 (63.24) 9 (50.00) 34 (68.00) 0.174
AF, n (%) 15 (22.06) 2 (11.11) 13 (26.00) 0.330
CHD, n (%) 37 (54.41) 8 (44.44) 29 (58.00) 0.322
Stroke, n (%) 14 (20.59) 4 (22.22) 10 (20.00) 1.000
Smoking, n (%) 24 (35.29) 6 (33.33) 18 (36.00) 0.839
Drinking, n (%) 34 (50.00) 10 (55.56) 24 (48.00) 0.582
Previous tumor history, n (%) 52 (76.47) 11 (61.11) 41 (82.00) 0.574
MT to stroke after tumor, month 6.15 ± 3.21 6.86 ± 2.26 5.64 ± 3.02 0.812
Diagnosis after stroke, n (%) 16 (23.53) 7 (38.89) 9 (18.00) 0.871
MT to tumor after stroke, month 12.39 ± 4.12 13.21 ± 3.22 10.18 ± 2.41 0.072
RBC (×1012/L) 4.51 ± 0.75 4.62 ± 0.90 4.47 ± 0.69 0.833
WBC (×109/L) 7.01 ± 2.10 7.76 ± 2.02 6.74 ± 2.08 0.810
PLT (×109/L) 314.22 ± 20.85 306.33 ± 29.53 317.06 ± 16.14 0.326
Hb, g/L 119.09 ± 10.34 122.56 ± 15.30 117.84 ± 7.69 0.231
LDL-C, mmol/L 4.11 ± 0.72 3.89 ± 0.70 4.19 ± 0.72 0.130
Hcy, μmol/L 18.35 ± 3.21 17.00 ± 3.40 18.84 ± 3.03a 0.047
Fib, g/L 4.30 ± 0.60 4.18 ± 0.57 4.34 ± 0.61 0.981
D-dimer, mg/L 1.89 ± 0.85 1.24 ± 0.70 2.12 ± 0.78a <0.001
TAT, ng/ml 6.93 ± 3.98 3.75 ± 1.40 8.07 ± 3.99a <0.001
One territory sign 7 (10.29) 4 (22.22) 3 (6.00) 0.136
Two territory sign 25 (36.76) 4 (22.22) 21 (42.00) 0.136
Three territory sign 30 (44.12) 4 (22.22) 26 (52.00)a 0.029
Cardiac valvular vegetations 13 (19.12) 2 (11.11) 11 (22.00) 0.511

CHD, coronary heart disease; AF, atrial fibrillation; MT, mean time; RBC, Red blood cell; WBC, White blood cell; PLT, Platelet; Hb, Hemoglobin; LDL-C, low-density lipoprotein cholesterol; Hcy, homocysteine; Fib, fibrinogen; TAT, thrombin-antithrombin complex.

a

P < 0.05, as compared to poor prognosis.